The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16
Open accessAbstract
The HIV-1-specific antibodies PG9 and PG16 show marked cross-isolate neutralization breadth and potency. Antibody neutralization has been shown to be dependent on the presence of N-linked glycosylation at position 160 in gp120. We show here that (i) the loss of several key glycosylation sites in the V1, V2, and V3 loops; (ii) the generation of pseudoviruses in the presence of various glycosidase inhibitors; and (iii) the growth of pseudoviruses in a mutant cell line (GnT1 −/− ) that alters envelope glycosylation patterns all have significant effects on the sensitivity of virus to neutralization by PG9 and PG16. However, the interaction of antibody is not inhibited by sugar monosaccharides corresponding to those found in glycans on the HIV surface. We show that some of the glycosylation effects described are isolate dependent and others are universal and can be used as diagnostic for the presence of PG9 and PG16-like antibodies in the sera of HIV-1-infected patients. The results suggest that PG9 and PG16 recognize a conformational epitope that is dependent on glycosylation at specific variable loop N-linked sites. This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257 · cited 1×
“It is argued that an effective HIV vaccine should include a component that induces a broadly neutralizing antibody response (2, 3, 21, 25, 32, 37, 39, 54).”
Background
Cited by
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011) · Science · doi:10.1126/science.1213256 · Cited by 694
Self-citationBonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I. S., Chuang, G.-Y., Druz, A., et al. (2014) · Nature · doi:10.1038/nature13601 · Cited by 420
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C.-H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359
Self-citationCharacteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G., & Stamatatos, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001251 · Cited by 315
Metadata
- Authors
- Doores, K. J., & Burton, D. R.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2010-10-15
- Volume
- 84
- Issue
- 20
- Pages
- 10510-10521
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2083627780
- Cited by
- 235
- References
- 1
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16. https://app.cochat.ai/papers/10.1128/jvi.00552-10
- The paper
- Doores, K. J., & Burton, D. R. (2010). Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16. Journal of Virology. https://doi.org/10.1128/jvi.00552-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.